GlassScriptPhysician profile
Jaime C Gonzalez
NPI 1316936461
$1,668.77
in general payments reported to CMS, 2019-2025
18 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $125 · 2021: $88.88 · 2022: $162 · 2023: $397 · 2024: $295 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $308.99 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $274.32 | 2019-2025 | Mounjaro |
| Neurocrine Biosciences, INC. | $238.63 | 2019-2024 | Ingrezza |
| Novo Nordisk INC | $176.24 | 2022-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $107.52 | 2024 | Auvelity |
| Abbvie INC. | $107.07 | 2021-2025 | |
| Mdd US Operations, LLC | $100.00 | 2023 | Gocovri |
| Idorsia Pharmaceuticals US INC | $89.15 | 2022 | |
| Abbott Laboratories | $58.46 | 2022-2023 | Freestyle Libre 2 |
| Pfizer INC. | $45.65 | 2022-2024 | |
| Janssen Biotech, INC. | $27.86 | 2023 | Tremfya |
| Dexcom, INC. | $24.10 | 2022 | |
| Exact Sciences Corporation | $20.61 | 2025 | Cologuard Collection Kit |
| Emergent Biosolutions INC. | $20.34 | 2019 | |
| Glaxosmithkline, LLC. | $18.95 | 2023 | Shingrix, Arexvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $17.58 | 2023 | Contrave, Onzetra Xsail |
| Shield Therapeutics INC | $16.93 | 2025 | |
| Phadia US INC. | $16.37 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.